Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | PDE8A | O60658 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884020 | 0.82 | — | — | |
| SCHEMBL31283877 | 0.82 | — | — | |
| SCHEMBL17884010 | 0.82 | HTT (0.46) | HTTACHEGRIN1GRIN2ABCHE | |
| SCHEMBL22258816 | 0.79 | NQO2 (0.30) | — | |
| SCHEMBL17873529 | 0.79 | HTT (0.44) | HTTACHEGRIN1GRIN2ABCHE | |
| SCHEMBL31284109 | 0.79 | NQO2 (0.30) | — | |
| SCHEMBL17873539 | 0.77 | HTT (0.41) | HTTACHEGRIN1GRIN2ABCHE | |
| SCHEMBL25987673 | 0.75 | HTT (0.42) | HTT | |
| SCHEMBL27301508 | 0.75 | HTT (0.42) | HTT | |
| SCHEMBL17873521 | 0.73 | ALDH1A1 (0.45) | HTTACHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-11304948-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3960735-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20200360383-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2020-11-19 | — | — | US | disclosed |
| CN-111574464-A | Quinazoline derivatives for the treatment of HIV | 吉利德科学公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-107278201-B | Quinazoline derivatives for the treatment of HIV | 吉利德科学公司 | 2020-05-19 | — | — | CN | disclosed |
| US-10548898-B2 | Quinazoline compounds | GILEAD SCIENCES INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170354656-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2017-12-14 | — | — | US | disclosed |
| EP-3237398-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304948-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
| US-20200360383-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
| US-10548898-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
| US-20170354656-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | HTT 383/4885ACHE 615/4885GRIN1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.